[{"id":"70f3da70-435a-4e8e-8765-2dd529fcdc8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05950165","created_at":"2023-07-20T15:09:24.726Z","updated_at":"2024-07-02T16:35:42.708Z","phase":"Phase 1/2","brief_title":"A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05950165","lead_sponsor":"Cho Pharma Inc.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHO-H01"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2023-07-18"},{"id":"1da8bbdd-5cfe-4a5a-9c87-f76926ee3f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT03221348","created_at":"2021-01-18T15:53:54.970Z","updated_at":"2024-07-02T16:37:14.530Z","phase":"Phase 1","brief_title":"A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma","source_id_and_acronym":"NCT03221348","lead_sponsor":"Cho Pharma Inc.","biomarkers":" CD20 • CD8 • CD4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHO-H01"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2018-01-24"}]